Wegovy vs Mounjaro: The Complete UK Comparison
Wegovy or Mounjaro UK: Understanding the Key Mechanism Differences
When comparing Wegovy or Mounjaro UK options, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone to reduce appetite and promote satiety after smaller meals. Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors simultaneously—a dual agonist approach that may influence blood sugar control and appetite regulation through multiple pathways.
Both prescription-only medicines work by affecting brain appetite centres, but their different receptor targets mean individual responses can vary significantly. Some patients find Wegovy's single GLP-1 pathway provides sufficient appetite control, whilst others may benefit from Mounjaro's dual mechanism. The choice between Wegovy or Mounjaro UK treatments ultimately depends on your individual clinical profile, which our GPhC-registered pharmacy team (#9012878) can assess through a comprehensive clinical evaluation.
Wegovy or Mounjaro UK Pricing: Complete Cost Comparison
When evaluating Wegovy or Mounjaro UK costs, pricing structures differ significantly between the treatments. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles include the Intro Duo (0.25mg & 0.5mg) for £169.99, whilst the Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25.
Mounjaro follows a different pricing structure with six dose levels from 2.5mg to 15mg, allowing more granular dose adjustments for patients who require slower titration. Both Wegovy or Mounjaro UK treatments require prescription-only medicine status and clinical assessment before supply. Our 2-pen and 3-pen bundles provide convenience benefits including Reliable Supply continuity and reduced ordering frequency, particularly valuable during periods of high demand for either treatment option.
Clinical Evidence: Wegovy or Mounjaro UK Trial Data
Clinical trials demonstrate both Wegovy and Mounjaro's efficacy in weight management when used alongside lifestyle modifications. In the STEP trials, patients taking Wegovy experienced an average of approximately clinically studied weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP programme included over 4,500 participants across multiple studies examining different patient populations.
Mounjaro's SURMOUNT trials showed varying weight loss percentages across different doses, though direct comparison between Wegovy or Mounjaro UK trial results requires careful consideration due to different study designs and patient populations. Both treatments are designed to work alongside a reduced-calorie diet and increased physical activity, with individual results varying significantly based on adherence to lifestyle modifications and personal metabolic factors.
How Wegovy Works: GLP-1 Mechanism for Wegovy or Mounjaro UK Patients
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a hormone naturally produced in your intestines after eating. This mechanism helps slow gastric emptying, meaning food remains in your stomach longer, promoting feelings of fullness and reducing the urge to eat between meals. The treatment also acts on appetite control centres in the brain, potentially reducing food cravings and the psychological drive to eat. Wegovy's once-weekly injection schedule helps maintain consistent hormone levels throughout the week, supporting sustained appetite regulation. When considering Wegovy or Mounjaro UK options, understanding that Wegovy's single-pathway approach may suit patients who respond well to GLP-1 stimulation alone, without requiring additional hormonal pathways.
Ordering Process: Accessing Wegovy or Mounjaro UK Through EverydayMeds
Our streamlined ordering process makes accessing either Wegovy or Mounjaro UK treatments straightforward and clinically safe. Begin with our 3-minute online clinical assessment, which gathers essential medical history, current medications, and weight management goals to help determine suitability for either treatment. Your assessment undergoes prescriber review within our standard 3 working days, or choose express review for approval within 24 hours if you need faster access. Once approved, both Wegovy and Mounjaro are dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our clinical team remains available throughout your treatment journey to address questions about dose escalation, side effect management, or switching between Wegovy or Mounjaro UK options if clinically appropriate.
Storage and Practical Considerations: Wegovy or Mounjaro UK Differences
Storage requirements present a key practical difference when choosing between Wegovy or Mounjaro UK treatments. Wegovy pens must be stored in the refrigerator at 2-8°C before first use but can remain at room temperature below 30°C for up to 6 weeks once removed from refrigeration—a significant advantage for frequent travellers or those with limited fridge space. Mounjaro requires similar refrigerated storage but only tolerates 21 days at room temperature, making Wegovy more flexible for extended travel or workplace storage. Both treatments use pre-filled injection pens designed for once-weekly subcutaneous administration, with clear dose escalation schedules printed on each pen to prevent confusion. The FlexTouch pen design used for Wegovy provides audible and tactile feedback to confirm successful injection, whilst both treatments require gradual dose increases over several months to minimise gastrointestinal side effects.
Wegovy or Mounjaro UK: Dose Escalation and Flexibility Comparison
The dose escalation pathways differ significantly between Wegovy or Mounjaro UK treatments, affecting how quickly patients reach their optimal therapeutic dose. Wegovy follows a 5-step escalation: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards. This structured approach provides predictable progression with well-established timeframes for each dose level. Mounjaro offers 6 dose levels from 2.5mg to 15mg, allowing more granular adjustments and potentially slower titration for patients experiencing side effects during escalation.
Some patients find Mounjaro's additional dose options helpful for fine-tuning their treatment, whilst others prefer Wegovy's straightforward progression pathway. Both Wegovy or Mounjaro UK treatments allow dose reduction if side effects occur, though returning to previous dose levels should be discussed with prescribers rather than self-managed. The flexibility to adjust dosing schedules makes both treatments suitable for patients with varying tolerance levels and treatment response patterns.
Making Your Choice: Expert Support for Wegovy or Mounjaro UK Decisions
Choosing between Wegovy or Mounjaro UK requires careful consideration of individual factors including medical history, lifestyle requirements, and treatment preferences. Our clinical team provides personalised guidance during your assessment, examining factors like previous weight management attempts, current medications that might interact differently with each treatment, and practical considerations such as travel frequency or storage limitations. Both treatments require commitment to lifestyle modifications including dietary changes and increased physical activity for optimal results. EverydayMeds supplies both options through our GPhC-registered pharmacy, ensuring you receive expert clinical oversight regardless of which treatment proves most suitable. Your prescriber can help determine whether Wegovy's established GLP-1 pathway or Mounjaro's dual mechanism approach aligns better with your clinical profile, with the flexibility to switch treatments if your initial choice requires adjustment.
Ready to start your weight management journey? Visit our weight loss collection to begin your clinical assessment for either Wegovy or Mounjaro UK treatment. Our experienced prescribers will review your individual needs and recommend the most appropriate option based on your medical history and treatment goals. Use code FIRST40 for new customers or DOSE25 for returning patients at checkout, with express review available for approval within 24 hours. Both treatments are available with next-day cold-chain delivery once approved, ensuring you can begin your chosen treatment without delay. Remember that successful weight management requires ongoing commitment to lifestyle changes alongside your chosen prescription treatment.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
